# Safety and Efficacy of SCM-AGH in Patients With Moderate to Severe Acute Pancreatitis

> **NCT04189419** · PHASE1,PHASE2 · COMPLETED · sponsor: **SCM Lifescience Co., LTD.** · enrollment: 36 (actual)

## Conditions studied

- Pancreatitis, Acute

## Interventions

- **BIOLOGICAL:** SCM-AGH
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04189419
- **Lead sponsor:** SCM Lifescience Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-12
- **Primary completion:** 2022-01-14
- **Final completion:** 2022-03-15
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04189419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04189419, "Safety and Efficacy of SCM-AGH in Patients With Moderate to Severe Acute Pancreatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04189419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*